my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
Astellas Pharma Canada, Inc., a Canadian affiliate of Tokyo-based Astellas Pharma Inc., is a pharmaceutical company dedicated to improving the health of people around the world through innovative and reliable pharmaceutical products. Astellas was formed in 2005 through the merger of two companies - more
Astellas Pharma Inc. and UCB S.A. announced that UCB Japan has received marketing approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for Cimzia® (certolizumab pegol). Cimzia®, under joint development in Japan, has been approved as a 200 mg syringe for subcutaneous injection for more
Abbott announced that it has signed an agreement to collaborate with Astellas Pharma Global Development in a Phase 3 clinical trial for ASP0113 (TransVax™), an investigational vaccine licensed from Vical Incorporated for preventing cytomegalovirus (CMV) reactivation in transplant patients.Under the more
MediGene AG announced that exclusive European rights to the cancer drug Eligard® have been transferred to Astellas Pharma Europe Ltd., with effect from March 1, 2011. This will trigger a second milestone payment from Astellas to MediGene, amounting to EUR 15 million, as agreed in the July 2010 cont more
Affiliation between the American Society of Pharmacometrics and the Journal of Pharmacokinetics and Pharmacodynamics Content Type Journal Article Pages 1-1 DOI 10.1007/s10928-011-9237-x Authors David Z. D’Argenio, University of Southern California, Los Angeles, CA, USA Marc R. Gastongua more
Deal watch: Aveo and Astellas to develop VEGF inhibitor for renal cell carcinoma Nature Reviews Drug Discovery 10, 248 (2011). doi:10.1038/nrd3420 Aveo Pharmaceuticals and Astellas Pharma have agreed to jointly develop and commercialize the oral vascular endothelial growth fac more
Introduction At present, only six drugs are indicated for the treatment of neuropathic pain. In 2010, two significant events impacted the neuropathic pain market: the launch of Qutenza (8% capsaicin patch; NeurogesX/Astellas) in the US and EU; and the high-profile failure of ralfinamide (NW-1029; N more
Theravance, Inc. (Theravance) is engaged in the discovery, development and commercialization of new medicines. Its drug discovery efforts are based on its expertise in multivalency. Multivalency involves the instantaneous attachment of a single molecule to multiple binding sites on biological target more
Introduction GlobalData, the industry analysis specialist, has released its new report, “Genital Herpes Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Genital Herpes Therapeutics market. The report identi more
Skip to content Management Team Board of Directors Scientific Advisors Clinical Advisors Contact Us Directions FLT3 Kinase AURORA Kinase BRAF Kinase Press Releases Events Ambit's powerful profiling technology, innovative licensing strategy, history of kinase expertise and pipeline of cancer therapeu more
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat critically ill patients with serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critical more
Skip to content Management Team Board of Directors Scientific Advisors Clinical Advisors Contact Us Directions FLT3 Kinase AURORA Kinase BRAF Kinase Press Releases Events Management Team Board of Directors Scientific Advisors Clinical Advisors Contact Us Directions Corporate Officers Alan Lewis Ch more
Watchlist
This is where you can add this topic to your personal favourites
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
